2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Ovarian Neoplasms
7
Neoplasms
5
Breast Neoplasms
3
Recurrence
2
Hypersensitivity
2
Fallopian Tube Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Kenny-Caffey syndrome, Type 1
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Fluorouracil
498
Bevacizumab
476
Oxaliplatin
450
Leucovorin
442
Irinotecan
408
Cetuximab
318
Capecitabine
317
pembrolizumab
142
Folfox protocol
128
Panitumumab
117
regorafenib
105
Colonoscopy
88
Nivolumab
82
IFL protocol
81
Drug Therapy
77
trifluridine tipiracil drug combination
73
Radiotherapy
66
HMPL-013
65
Blood Specimen Collection
52
Gemcitabine
49
Specimen Handling
47
Standard of Care
45
Neoadjuvant Therapy
45
Magnetic Resonance Spectroscopy
44
Biopsy
44
Chemotherapy, Adjuvant
41
Trifluridine
40
atezolizumab
39
Cyclophosphamide
39
Surveys and Questionnaires
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled